D J P van Uden1, R Bretveld2, S Siesling2,3, J H W de Wilt4, C F J M Blanken-Peeters5. 1. Department of Surgical Oncology, Radboud University Medical Center Nijmegen, Geert Grootplein Zuid 10, 6525 GA, Nijmegen, The Netherlands. djpvanuden@gmail.com. 2. Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Hoog Catharijne, Godebaldkwartier 419, 3511 DT, Utrecht, The Netherlands. 3. Department of Health Technology and Services Research, MIRA Institute for Biomedical Technology and Technical Medicine, Drienerlolaan 5, 7522 NB, Enschede, The Netherlands. 4. Department of Surgical Oncology, Radboud University Medical Center Nijmegen, Geert Grootplein Zuid 10, 6525 GA, Nijmegen, The Netherlands. 5. Department of Surgery, Rijnstate Hospital, Arnhem, Wagnerlaan 55, 6815 AD, Arnhem, The Netherlands.
Abstract
PURPOSE: Locally advanced breast cancer (LABC) includes inflammatory breast cancer (IBC) as well as non-inflammatory LABC (NI-LABC). The aim of this population-based study was to compare the tumour characteristics, treatment and relative survival of IBC and NI-LABC patients. METHODS: Patients with either IBC (cT4d) or NI-LABC (cT4a-c) were identified from the nationwide Netherlands Cancer Registry from the period 1989-2015. In each group, patients are divided into three time periods in order to perform a trend analysis: 1989-1997, 1998-2006, and 2007-2015. RESULTS: IBC comprised 1.1% and NI-LABC 4.6% of all diagnosed breast cancer patients. IBC patients showed more nodal metastases (77.8 vs. 69.7%, P < 0.001) and distant metastases (39.7 vs. 34.1%, P < 0.001). IBC tumours were more often triple negative (23.2 vs. 12.8%, P < 0.001) and poorly differentiated (69.8 vs. 53.8%, P < 0.001). Trimodality therapy (neoadjuvant chemotherapy, surgery and adjuvant radiotherapy) was more often applied over time in both groups (IBC: 23.7%-56.0%-68.6%; NI-LABC: 3.7%-25.9%-43.6%; P trend < 0.001). In IBC patients, relative 5-year survival was significantly shorter than in patients with NI-LABC (30.2 vs. 45.1%, P < 0.001). The relative survival significantly improved for IBC from 17.2% (1989-1997) to 30.0 and 38.9% for the last two time periods (1998-2006: P < 0.001; 2007-2015: P < 0.001). In contrast, survival did not significantly improve in NI-LABC breast cancer: from 44.7% (1989-1997) to 44.0 and 48.4% (1998-2006: P = 0.483; 2007-2015: P = 0.091). CONCLUSIONS: IBC has tumour characteristics that determine its aggressive biology compared to NI-LABC. Trimodality therapy was increasingly applied in both groups, but did not improve survival in NI-LABC. Although relative survival in IBC patients has improved during the last decades, it remains a disease with a dismal prognosis.
PURPOSE: Locally advanced breast cancer (LABC) includes inflammatory breast cancer (IBC) as well as non-inflammatory LABC (NI-LABC). The aim of this population-based study was to compare the tumour characteristics, treatment and relative survival of IBC and NI-LABCpatients. METHODS:Patients with either IBC (cT4d) or NI-LABC (cT4a-c) were identified from the nationwide Netherlands Cancer Registry from the period 1989-2015. In each group, patients are divided into three time periods in order to perform a trend analysis: 1989-1997, 1998-2006, and 2007-2015. RESULTS: IBC comprised 1.1% and NI-LABC 4.6% of all diagnosed breast cancerpatients. IBC patients showed more nodal metastases (77.8 vs. 69.7%, P < 0.001) and distant metastases (39.7 vs. 34.1%, P < 0.001). IBC tumours were more often triple negative (23.2 vs. 12.8%, P < 0.001) and poorly differentiated (69.8 vs. 53.8%, P < 0.001). Trimodality therapy (neoadjuvant chemotherapy, surgery and adjuvant radiotherapy) was more often applied over time in both groups (IBC: 23.7%-56.0%-68.6%; NI-LABC: 3.7%-25.9%-43.6%; P trend < 0.001). In IBC patients, relative 5-year survival was significantly shorter than in patients with NI-LABC (30.2 vs. 45.1%, P < 0.001). The relative survival significantly improved for IBC from 17.2% (1989-1997) to 30.0 and 38.9% for the last two time periods (1998-2006: P < 0.001; 2007-2015: P < 0.001). In contrast, survival did not significantly improve in NI-LABC breast cancer: from 44.7% (1989-1997) to 44.0 and 48.4% (1998-2006: P = 0.483; 2007-2015: P = 0.091). CONCLUSIONS: IBC has tumour characteristics that determine its aggressive biology compared to NI-LABC. Trimodality therapy was increasingly applied in both groups, but did not improve survival in NI-LABC. Although relative survival in IBC patients has improved during the last decades, it remains a disease with a dismal prognosis.
Entities:
Keywords:
Epidemiology; Inflammatory breast cancer; Locally advanced breast cancer; Survival; The Netherlands; Treatment
Authors: Hugo Arias-Pulido; Ashley Marie Cimino-Mathews; Nabila Chaher; Clifford Ray Qualls; Nancy Joste; Cecile Colpaert; Jonathan Douglas Marotti; Mary Dickinson Chamberlin; Maxwell Gabriel Foisey; Eric Robert Prossnitz; Leisha Ann Emens; Steven Fiering Journal: Breast Cancer Res Treat Date: 2021-09-20 Impact factor: 4.872
Authors: Dominique J P van Uden; J Hans W de Wilt; Carla Meeuwis; Charlotte F J M Blanken-Peeters; Ritse M Mann Journal: Breast Care (Basel) Date: 2017-08-29 Impact factor: 2.860
Authors: D J P van Uden; M C van Maaren; L J A Strobbe; P Bult; J J van der Hoeven; S Siesling; J H W de Wilt; C F J M Blanken-Peeters Journal: Breast Cancer Res Date: 2019-10-17 Impact factor: 6.466
Authors: Daniel Alonso-Miguel; Guillermo Valdivia; Laura Peña; Hugo Arias-Pulido; Diego Guerrera; Maria Dolores Perez-Alenza; Stanislav Pantelyushin; Angela Alonso-Diez; Veronique Beiss; Steven Fiering; Nicole F Steinmetz; Maria Suarez-Redondo; Johannes Vom Berg Journal: J Immunother Cancer Date: 2022-03 Impact factor: 13.751